Less than a year after speeding into the European Society of Cardiology's atrial fibrillation guidelines with a class 1 recommendation, the role of dronedarone (Multaq, Sanofi) in the treatment of AF ...

In an updated safety communication the FDA announced it was adding new warnings to the dronedarone (Multaq, Sanofi) label. Based on results from the PALLAS trial, which was discontinued early due to ...

Hammill's colleague, HRS past-president Dr Michael Cain, agreed. "We desperately would benefit from an antiarrhythmic drug that worked as well as amiodarone but had an improved safety profile." The ...

Dronedarone is associated with a reduction in recurrent AF and may have other potential benefits. According to Richard L. Page, MD, president of the Heart Rhythm Society and a professor of medicine ...

Please provide your email address to receive an email when new articles are posted on . Dronedarone is a noniodinated benzofuran derivative of amiodarone that was specifically designed to improve the ...

Getting to the Heart of the Matter: A Review of Potential Drug Interactions With Cardiac Medications The use of digoxin in atrial fibrillation has remained controversial because of its narrow ...

Review the side-effects of Dronedarone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and contributing significantly to cancer-related mortality globally. Despite ...

Two phase 3 trials of dronedarone, a novel class III antiarrhythmic agent currently in development worldwide, have demonstrated that the drug is safe and effective for the maintenance of normal sinus ...

The Appraisal Committee considered evidence submitted by the manufacturer of dronedarone and a review of this submission by the Evidence Review Group (ERG). The main clinical evidence on dronedarone ...